Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 51

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain

D'Abramo, M, Bešker, N, Desideri, A, Levine, A J, Melino, G, Chillemi, G·2016·Oncogene
DOI 10.1038/onc.2015.388
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2015.388

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 110

  1. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 2013; 41: D962–D969. · DOI · Paper page
  2. Yoshida K, Miki Y . The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 2010; 101: 831–835. · DOI
  3. Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ . The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 2009; 14: 336–347. · DOI
  4. Giono LE, Manfredi JJ . The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209: 13–20. · DOI · Paper page
  5. Feng H, Jenkins LMM, Durell SR, Hayashi R, Mazur SJ, Cherry S et al. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 2009; 17: 202–210. · DOI
  6. Rowell JP, Simpson KL, Stott K, Watson M, Thomas JO . HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. Structure 2012; 20: 2014–2024. · DOI · Paper page
  7. Bochkareva E, Kaustov L, Ayed A, Yi G-S, Lu Y, Pineda-Lucena A et al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci USA 2005; 102: 15412–15417. · DOI · Paper page
  8. Jeffrey PD, Gorina S, Pavletich NP . Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995; 267: 1498–1502. · DOI · Paper page
  9. Tidow H, Melero R, Mylonas E, Freund SMV, Grossmann JG, Carazo JM et al. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 2007; 104: 12324–12329. · DOI · Paper page
  10. Chillemi G, Davidovich P, D’Abramo M, Mametnabiev T, Garabadzhiu AV, Desideri A et al. Molecular dynamics of the full-length p53 monomer. Cell Cycle 2013; 12: 3098–3108. · DOI · Paper page
  11. Lubin DJ, Butler JS, Loh SN . Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. J Mol Biol 2010; 395: 705–716. · DOI
  12. Wassman CD, Baronio R, Demir Ö, Wallentine BD, Chen C-K, Hall LV et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 2013; 4: 1407. · DOI · Paper page
  13. Demir Ö, Baronio R, Salehi F, Wassman CD, Hall L, Hatfield GW et al. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput Biol 2011; 7: e1002238. · DOI · Paper page
  14. Lu Q, Tan Y-H, Luo R . Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007; 111: 11538–11545. · DOI
  15. McCammon JA, Harvey SC . Dynamics of Proteins and Nucleic Acids. Cambridge University Press: Cambridge, UK, 1988, pp 289–302.
  16. Van Aalten DMF, de Groot BL, Findlay JBC, Berendsen HJC, Amadei A . A comparison of techniques for calculating protein essential dynamics. J Comput Chem 1997; 18: 169–181. · DOI
  17. Amadei A, Linssen ABM, Berendsen HJC . Essential dynamics of proteins. Proteins Struct Funct Genet 1993; 17: 412–425. · DOI · Paper page
  18. Kern D, Zuiderweg ERP . The role of dynamics in allosteric regulation. Curr Opin Struct Biol 2003; 13: 748–757. · DOI · Paper page
  19. Lange OF, Grubmüller H . Full correlation analysis of conformational protein dynamics. Proteins Struct Funct Genet 2008; 70: 1294–1312. · DOI
  20. Melero R, Rajagopalan S, Lázaro M, Joerger AC, Brandt T, Veprintsev DB et al. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci USA 2011; 108: 557–562. · DOI · Paper page
  21. Chen Y, Dey R, Chen L . Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure 2010; 18: 246–256. · DOI · Paper page
  22. Petty TJ, Emamzadah S, Costantino L, Petkova I, Stavridi ES, Saven JG et al. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J 2011; 30: 2167–2176. · DOI · Paper page
  23. Pan Y, Nussinov R . Lysine120 interactions with p53 response elements can allosterically direct p53 organization. PLoS Comput Biol 2010; 6:: 1–13.
  24. Lavery R, Moakher M, Maddocks JH, Petkeviciute D, Zakrzewska K . Conformational analysis of nucleic acids revisited: Curves+. Nucleic Acids Res 2009; 37: 5917–5929. · DOI · Paper page
  25. Lu XJ, Olson WK . 3DNA: a software package for the analysis, rebuilding and visualization of three-dimensional nucleic acid structures. Nucleic Acids Res 2003; 31: 5108–5121. · DOI · Paper page
  26. Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E et al. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Mol Cell 2015; 57: 1034–1046. · DOI · Paper page
  27. Spolar RS, Record MT . Coupling of local folding to site-specific binding of proteins to DNA. Science 1994; 263: 777–784. · DOI · Paper page
  28. Jiang P, Du W, Mancuso A, Wellen KE, Yang X . Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013; 493: 689–693. · DOI · Paper page
  29. Venkatanarayan A, Raulji P, Norton W, Chakravarti D, Coarfa C, Su X et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 2014; 517: 626–630. · DOI
  30. Méniel V, Megges M, Young MA, Cole A, Sansom OJ, Clarke AR . Apc and p53 interaction in DNA damage and genomic instability in hepatocytes. Oncogene 2014; 34: 4118–4129. · DOI
  31. Van Nostrand JL, Brady Ca, Jung H, Fuentes DR, Kozak MM, Johnson TM et al. Inappropriate p53 activation during development induces features of CHARGE syndrome. Nature 2014; 514: 228–232. · DOI · Paper page
  32. Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ 2014; 21: 1419–1431. · DOI
  33. Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M et al. Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response. Cell Death Differ 2014; 21: 1409–1418. · DOI
  34. Zhu L, Lu Z, Zhao H . Antitumor mechanisms when pRb and p53 are genetically inactivated. Oncogene 2014; 34: 4547–4557. · DOI
  35. Merlo P, Frost B, Peng S, Yang YJ, Park PJ, Feany M . p53 prevents neurodegeneration by regulating synaptic genes. Proc Natl Acad Sci USA 2014; 111: 18055–18060. · DOI
  36. Dudgeon C, Chan C, Kang W, Sun Y, Emerson R, Robins H et al. The evolution of thymic lymphomas in p53 knockout mice. Genes Dev 2014; 28: 2613–2620. · DOI
  37. Tan EH, Morton JP, Timpson P, Tucci P, Melino G, Flores ER et al. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene 2014; 33: 3325–3333. · DOI
  38. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269–1283. · DOI · Paper page
  39. Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA . PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome. Oncogene 2014; 33: 1621–1628. · DOI
  40. Kim J, Nakasaki M, Todorova D, Lake B, Yuan C-Y, Jamora C et al. P53 induces skin aging by depleting Blimp1(+) sebaceous gland cells. Cell Death Dis 2014; 5: e1141. · DOI
  41. Fatt MP, Cancino GI, Miller FD, Kaplan DR . P63 and P73 coordinate P53 function to determine the balance between survival, cell death, and senescence in adult neural precursor cells. Cell Death Differ 2014; 21: 1546–1559. · DOI
  42. Rufini A, Tucci P, Celardo I, Melino G . Senescence and aging: the critical roles of p53. Oncogene 2013; 32: 5129–5143. · DOI · Paper page
  43. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G . The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12: 259–265. · DOI · Paper page
  44. Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T . One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006; 9: 288–306. · DOI
  45. Tomasini R, Mak TW, Melino G . The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18: 244–252. · DOI
  46. Buckley NE, D’Costa Z, Kaminska M, Mullan PB . S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. Cell Death Dis 2014; 5: e1070. · DOI
  47. Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H et al. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis 2014; 5: e1108. · DOI
  48. Foijer F, Xie SZ, Simon JE, Bakker PL, Conte N, Davis SH et al. Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress. Proc Natl Acad Sci USA 2014; 111: 13427–13432. · DOI
  49. Mello SS, Attardi LD . Not all p53 gain-of-function mutants are created equal. Cell Death Differ 2013; 20: 855–857. · DOI
  50. Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P et al. P73 regulates serine biosynthesis in cancer. Oncogene 2013; 33: 5039–5046. · DOI
  51. Evstafieva AG, Garaeva AA, Khutornenko AA, Klepikova AV, Logacheva MD, Penin AA et al. A sustained deficiency of mitochondrial respiratory complex III induces an apoptotic cell death through the p53-mediated inhibition of pro-survival activities of the activating transcription factor 4. Cell Death Dis 2014; 5: e1511. · DOI
  52. Peuget S, Bonacci T, Soubeyran P, Iovanna J, Dusetti NJ . Oxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation. Cell Death Differ 2014; 21: 1107–1118. · DOI
  53. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 2014; 21: 612–623. · DOI
  54. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 2012; 26: 2009–2014. · DOI
  55. Drosten M, Sum EYM, Lechuga CG, Simón-Carrasco L, Jacob HKC, García-Medina R et al. Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci USA 2014; 111: 15155–15160. · DOI · Paper page
  56. Zhang H-H, Li S-Z, Zhang Z-Y, Hu X-M, Hou P-N, Gao L et al. Nemo-like kinase is criticalor p53 stabilization and function in response to DNA damage. Cell Death Differ 2014; 21: 1656–1663. · DOI
  57. Tang Z, Chen W-Y, Shimada M, Nguyen UTT, Kim J, Sun X-J et al. SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell 2013; 154: 297–310. · DOI
  58. Dashzeveg N, Taira N, Lu Z-G, Kimura J, Yoshida K . Palmdelphin, a novel target of p53 with Ser46 phosphorylation, controls cell death in response to DNA damage. Cell Death Dis 2014; 5: e1221. · DOI
  59. Li D, Yallowitz A, Ozog L, Marchenko N . A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis 2014; 5: e1194. · DOI
  60. Manzl C, Fava LL, Krumschnabel G, Peintner L, Tanzer MC, Soratroi C et al. Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on caspase-2 or the PIDDosome. Cell Death Dis 2013; 4: e942. · DOI
  61. Phesse TJ, Myant KB, Cole AM, Ridgway RA, Pearson H, Muncan V et al. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death Differ 2014; 21: 956–966. · DOI
  62. Gorrini C . Discovery of a p53 variant that controls metastasis. Proc Natl Acad Sci USA 2014; 111: 11576–11577. · DOI
  63. Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM et al. P53Ψ is a transcriptionally inactive P53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci USA 2014; 111: E3287–E3296. · DOI · Paper page
  64. Solomon H, Sharon M, Rotter V . Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ. Cell Death Differ 2014; 21: 1347–1349. · DOI
  65. Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon J-C . Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ 2014; 21: 1377–1387. · DOI
  66. Hoffman Y, Bublik DR, Pilpel Y, Oren M . miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ 2014; 21: 302–309. · DOI
  67. Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R et al. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2015; 112: 2169–2174. · DOI
  68. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M et al. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ 2014; 21: 774–782. · DOI
  69. Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev 2014; 28: 438–450. · DOI · Paper page
  70. Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D et al. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death Dis 2014; 5: e1564. · DOI
  71. Lezina L, Purmessur N, Antonov AV, Ivanova T, Karpova E, Krishan K et al. miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress. Cell Death Dis 2013; 4: e953. · DOI
  72. Zhang E, Yin D, Sun M, Kong R, Liu X, You L et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis 2014; 5: e1243. · DOI · Paper page
  73. Ren Z-J, Nong X-Y, Lv Y-R, Sun H-H, An P-P, Wang F et al. Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. Cell Death Dis 2014; 5: e1387. · DOI
  74. Gomes LR, Vessoni AT, Menck CFM . Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene 2015, e-pub ahead of print 26 January 2015 doi:10.1038/onc.2014.461. · DOI
  75. Simon HU, Yousefi S, Schmid I, Friis R . ATG5 can regulate p53 expression and activation. Cell Death Dis 2014; 5: e1339. · DOI
  76. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP et al. P73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ 2013; 20: 1415–1424. · DOI
  77. Garufi A, Pucci D, D’Orazi V, Cirone M, Bossi G, Avantaggiati ML et al. Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis 2014; 5: e1271. · DOI
  78. Ci Y, Shi K, An J, Yang Y, Hui K, Wu P et al. ROS inhibit autophagy by downregulating ULK1 mediated by the phosphorylation of p53 in selenite-treated NB4 cells. Cell Death Dis 2014; 5: e1542. · DOI
  79. Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G et al. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis 2014; 5: e1203. · DOI
  80. Pant V, Lozano G . Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 2014; 28: 1739–1751. · DOI · Paper page
  81. Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM et al. XDepletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-Null tumors. Cell 2013; 155: 844–857. · DOI · Paper page
  82. Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H . RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis 2014; 5: e1318. · DOI
  83. Li H, Zhang Y, Ströse A, Tedesco D, Gurova K, Selivanova G . Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ 2014; 21: 1522–1534. · DOI
  84. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58–70. · DOI
  85. Malatesta M, Peschiaroli A, Memmi EM, Zhang J, Antonov A, Green DR et al. The Cul4A–DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity. Oncogene 2012; 32: 4721–4726. · DOI
  86. Fan Y-H, Cheng J, Vasudevan Sa, Dou J, Zhang H, Patel RH et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis 2013; 4: e867. · DOI · Paper page
  87. Zaccara S, Tebaldi T, Pederiva C, Ciribilli Y, Bisio A, Inga A . P53-directed translational control can shape and expand the universe of P53 target genes. Cell Death Differ 2014; 21: 1522–1534. · DOI
  88. Brune M, Müller M, Melino G, Bierhaus A, Schilling T, Nawroth PP . Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation. Oncogene 2012; 32: 1460–1468. · DOI
  89. Han F, Liu W, Jiang X, Shi X, Yin L, Ao L et al. SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer. Oncogene 2014; 34: 4391–4402. · DOI
  90. Link N, Kurtz P, O’Neal M, Garcia-Hughes G, Abrams JM . A p53 enhancer region regulates target genes through chromatin conformations in cis and in trans. Genes Dev 2013; 27: 2433–2438. · DOI
  91. Saldaña-Meyer R, González-Buendía E, Guerrero G, Narendra V, Bonasio R, Recillas-Targa F et al. CTCF regulates the human p53 gene through direct interaction with its natural antisense transcript, Wrap53. Genes Dev 2014; 28: 723–734. · DOI · Paper page
  92. Terrinoni A, Pagani IS, Zucchi I, Chiaravalli AM, Serra V, Rovera F et al. OTX1 expression in breast cancer is regulated by p53. Oncogene 2011; 30: 3096–3103. · DOI
  93. Zambetti GP . Expanding the reach of the p53 tumor suppressor network. Cell Death Differ 2014; 21: 505–506. · DOI
  94. Wang G, Fersht AR . Propagation of aggregated p53: cross-reaction and coaggregation vs. seeding. Proc Natl Acad Sci USA 2015; 112: 2443–2448. · DOI · Paper page
  95. Wang G, Fersht AR . Mechanism of initiation of aggregation of p53 revealed by φ-value analysis. Proc Natl Acad Sci USA 2015; 112: 2437–2442. · DOI
  96. Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V et al. P53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2014; 34: 3605–3616. · DOI
  97. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS et al. Regulation of p53 activity through lysine methylation. Nature 2004; 432: 353–360. · DOI · Paper page
  98. Carr SM, Munro S, La Thangue NB . Lysine methylation and the regulation of p53. Essays Biochem 2012; 52: 79–92. · DOI
  99. Koshland DE . Application of a Theory of Enzyme Specificity to Protein Synthesis. Proc Natl Acad Sci USA 1958; 44: 98–104. · DOI · Paper page
  100. Johnson KA . Role of induced fit in enzyme specificity: a molecular forward/reverse switch. J Biol Chem 2008; 283: 26297–26301. · DOI · Paper page
  101. Emamzadah S, Tropia L, Vincenti I, Falquet B, Halazonetis TD . Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein. J Mol Biol 2014; 426: 936–944. · DOI
  102. Oldfield CJ, Meng J, Yang JY, Yang MQ, Uversky VN, Dunker AK . Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners. BMC Genomics 2008; 9: S1. · DOI · Paper page
  103. Sali A, Blundell TL . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779–815. · DOI · Paper page
  104. Kuszewski J, Gronenborn AM, Clore GM . Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J Am Chem Soc 1999; 121: 2337–2338. · DOI · Paper page
  105. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013; 29: 845–854. · DOI · Paper page
  106. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C . Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins Struct Funct Genet 2006; 65: 712–725. · DOI · Paper page
  107. Darden T, York D, Pedersen L . Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089. · DOI · Paper page
  108. Kabsch W, Sander C . Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577–2637. · DOI · Paper page
  109. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA . Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001; 98: 10037–10041. · DOI · Paper page
  110. Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33–38. · DOI · Paper page

Cited by

See all 51

Metadata

Authors
D'Abramo, M., Bešker, N., Desideri, A., Levine, A. J., Melino, G., & Chillemi, G.
ORCID
Chillemi, G
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2015-10-19
Volume
35
Issue
25
Pages
3272-3281
ISSN
  • 0950-9232
  • 1476-5594
DOI
10.1038/onc.2015.388
Cited by
51
References
11
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. https://app.cochat.ai/papers/10.1038/onc.2015.388
The paper
D'Abramo, M., Bešker, N., Desideri, A., Levine, A. J., Melino, G., & Chillemi, G. (2016). The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. Oncogene. https://doi.org/10.1038/onc.2015.388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.